



Sample Information

Patient Name: 黃美琴
Gender: Female
ID No.: T202239035
History No.: 27055523
Age: 68

Ordering Doctor: DOC4205A 柯博伸
Ordering REQ.: 0CQCRCK
Signing in Date: 2023/08/31

Path No.: M112-00240
MP No.: MY23064
Assay: Oncomine Myeloid Assay
Sample Type: Bone Marrow
Bone Marrow Aspirating Date: 2023/08/24

Reporting Doctor: DOC5444B 楊靜芬 (Phone: 8#5444)

Note:

Sample Cancer Type: Acute Myeloid Leukemia

Table of Contents	Page	Report Highlights
Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)	2	1 Relevant Biomarkers
Biomarker Descriptions	2	6 Therapies Available
Relevant Therapy Summary	3	0 Clinical Trials
Relevant Therapy Details	4	
Diagnostic Details	7	

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IA	NPM1 p.(W288Cfs*12) c.863_864insTCTG nucleophosmin 1 Allele Frequency: 43.87%	allogeneic stem cells cytarabine cytarabine + daunorubicin cytarabine + idarubicin cytarabine + mitoxantrone gemtuzumab ozogamicin + chemotherapy	None	0
Diagnostic significance: Acute Myeloid Leukemia				

Public data sources included in relevant therapies: FDA1, NCCN, EMA2, ESMO
Public data sources included in diagnostic significance: NCCN, ESMO

Prevalent cancer biomarkers without relevant evidence based on included data sources

DNMT3A p.(R882C) c.2644C>T, KRAS p.(G12D) c.35G>A

Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
DNMT3A	p.(R882C)	c.2644C>T	COSM53042	chr2:25457243	43.24%	NM_022552.4	missense	1998
NPM1	p.(W288Cfs*12)	c.863_864insTCTG	COSM17559	chr5:170837547	43.87%	NM_002520.6	frameshift Insertion	1990
KRAS	p.(G12D)	c.35G>A	COSM521	chr12:25398284	20.51%	NM_033360.4	missense	1989
TET2	p.(P1237L)	c.3710C>T	.	chr4:106164842	3.70%	NM_001127208.2	missense	2000

Biomarker Descriptions

DNMT3A (DNA methyltransferase 3 alpha)

Background: The DNMT3A gene encodes the DNA methyltransferase 3 alpha which functions as a de novo methyltransferase (DNMT) with equal methylation efficiency for unmethylated and hemimethylated DNA¹. Methylation of DNA occurs at CpG islands, a region of DNA consisting of sequential cytosine/guanine dinucleotide pairs. CpG island methylation plays an important role in development as well as stem cell regulation. Alterations to global DNA methylation patterns are dependent on DNMTs, which are associated with cancer initiation and progression^{2,3}.

Alterations and prevalence: DNMT3A mutations are observed in approximately 25% of all acute myeloid leukemia (AML) including 29-34% of AML with normal karyotype (NK-AML)^{4,5,6,7,8,9,10}. Mutations in DNMT3A are also reported in 12-18% of myelodysplastic syndromes (MDS) as well as 4-6% of melanoma, lung adenocarcinoma, and uterine cancer^{9,11}. The majority of mutations in DNMT3A are missense however, frameshift, nonsense, and splice site mutations have also been reported^{4,9}. Missense mutations at R882 are most prevalent and are observed to coexist with NPM1 and FLT3 mutations^{12,13}. The R882 mutations occur at the dimer/tetramer interface within the catalytic domain, which leads to disruption of DNMT3A tetramerization and loss of CpG methylation^{14,15}. However, DNMT3A mutations observed in AML at positions other than R882 also contribute to pathogenesis by mechanisms that do not involve methyltransferase activity¹⁶.

Potential relevance: DNMT3A mutations confer shorter overall survival (OS) in patients with AML including those with NK-AML^{4,7,8,13}. DNMT3A mutations are a useful in the diagnosis of angioimmunoblastic T-cell lymphoma (AITCL) when trying to differentiate from other peripheral T-cell lymphomas (PTCL)¹⁷.

KRAS (KRAS proto-oncogene, GTPase)

Background: The KRAS proto-oncogene encodes a GTPase that functions in signal transduction and is a member of the RAS superfamily which also includes NRAS and HRAS. RAS proteins mediate the transmission of growth signals from the cell surface to the nucleus via the PI3K/AKT/MTOR and RAS/RAF/MEK/ERK pathways, which regulate cell division, differentiation, and survival^{18,19,20}.

Alterations and prevalence: Recurrent mutations in RAS oncogenes cause constitutive activation and are found in 20-30% of cancers. KRAS mutations are observed in up to 10-20% of uterine cancer, 30-35% of lung adenocarcinoma and colorectal cancer, and about 60% of pancreatic cancer⁹. The majority of KRAS mutations consist of point mutations occurring at G12, G13, and Q61^{9,21,22}. Mutations at A59, K117, and A146 have also been observed but are less frequent^{23,24}.

Potential relevance: The FDA has approved the small molecule inhibitors, sotorasib²⁵ (2021) and adagrasib²⁶ (2022), for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The FDA has also granted breakthrough therapy designation (2022) to the KRAS G12C inhibitor, GDC-6036²⁷, for KRAS G12C mutation in non-small cell lung cancer. The small molecular inhibitor, RO-5126766, was granted breakthrough designation (2021) alone for KRAS G12V mutant non-small cell lung cancer or in combination with defactinib, for KRAS mutant endometrial carcinoma and KRAS G12V mutant non-small cell lung cancer²⁸. The PLK1 inhibitor, onvansertib²⁹, was granted fast track designation (2020) in combination with bevacizumab and FOLFIRI for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). Additionally, the SHP2 inhibitor, BBP-398³⁰ was granted fast track designation (2022) in combination with sotorasib for previously treated patients with KRAS G12C-mutated metastatic NSCLC. The EGFR antagonists, cetuximab³¹ and panitumumab³², are contraindicated for treatment of colorectal cancer patients with KRAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146)²⁴. Additionally, KRAS mutations are associated with poor prognosis in NSCLC³³.

Biomarker Descriptions (continued)

NPM1 (nucleophosmin 1)

Background: The NPM1 gene encodes the nucleophosmin protein, a histone chaperone of the nucleophosmin/nucleoplasmin family, which also includes NPM2 and NPM3³⁴. NPM1 functions as an oncogene and tumor suppressor, and is important in maintaining genomic stability, DNA repair, and apoptosis^{34,35}. NPM1 has a highly conserved N-terminal region which constitutes the core domain responsible for oligomerization, an acidic domain, a nuclear localization signal, and a disorganized C-terminal region which is required for nucleolar localization³⁴. Oligomerization of NPM1 localizes the protein in the nucleus of proliferating cells where it binds to Akt in response to growth factor stimulation and escapes proteolytic degradation by caspase activity, thereby promoting cell survival^{34,35}. NPM1 is one of the most frequently altered genes in hematological cancers³⁶. Most NPM1 mutations occur in the C-terminus, impacting protein folding or the nucleolar localization signal, and result in the localization of NPM1 to the cytoplasm (NPMc) instead of to the nucleus³⁴.

Alterations and prevalence: NPM1 mutations are observed in 45-60% of AML with a normal karyotype (NK-AML), 28-35% of de novo acute myeloid leukemia (AML) and are frequently co-mutated with DNMT3A and/or FLT3-ITD^{10,37,38}. NPM1 fusions are associated with distinct partner genes in acute promyelocytic leukemia (APL), anaplastic large-cell lymphoma (ALCL), AML, and myelodysplasia³⁶. Specifically, NPM1-ALK fusion is found in 30% of all ALCL and this specific fusion is observed in 85% of ALK-positive ALCL³⁴. The t(5;17)(q35;q21) translocation that results in NPM1-RARA fusion is observed in APL³⁹.

Potential relevance: Mutation of NPM1 is recognized as a diagnostic entity for AML with NPM1 mutation by the World Health Organization (WHO)⁴⁰. NPM1 mutations are associated with better outcomes, increased complete remission, improved overall survival, and favorable risk in AML^{10,38,41}. Concurrent expression of FLT-ITD with mutant or wild-type NPM1 (when lacking adverse risk genetic lesions) confers intermediate risk in AML^{10,41}. The NPM1 frameshift mutation W288fs*12 is associated with poor prognosis in myelodysplastic syndrome (MDS)¹¹. The ALK-NPM1 fusion and translocation t(2;5)(p23;q35) which leads to an ALK-NPM1 fusion is diagnostic of ALK-positive anaplastic large cell lymphoma^{17,42}.

Relevant Therapy Summary

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

NPM1 p.(W288Cfs*12) c.863_864insTCTG

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
Allogeneic hematopoietic stem cell transplantation	×	●	×	×	×
cytarabine	×	●	×	×	×
cytarabine + daunorubicin	×	●	×	×	×
cytarabine + idarubicin	×	●	×	×	×
cytarabine + mitoxantrone	×	●	×	×	×
gemtuzumab ozogamicin + cytarabine + daunorubicin	×	●	×	×	×
gemtuzumab ozogamicin + cytarabine + fludarabine + idarubicin + filgrastim	×	●	×	×	×

Relevant Therapy Details

Current NCCN Information

- ☒ In this cancer type ☐ In other cancer type ☒ In this cancer type and other cancer types

NCCN information is current as of 2023-07-03. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/what-we-do/international-adaptations.

Some variant specific evidence in this report may be associated with a broader set of alterations from the NCCN Guidelines. Specific variants listed in this report were sourced from approved therapies or scientific literature. These therapeutic options are appropriate for certain population segments with cancer. Refer to the NCCN Guidelines® for full recommendation.

NPM1 p.(W288Cfs*12) c.863_864insTCTG

☒ Allogeneic hematopoietic stem cell transplantation

Cancer type: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Other criteria: FLT3 ITD negative

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Consolidation therapy)

Reference: NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]

☒ cytarabine

Cancer type: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Other criteria: FLT3 ITD negative

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Consolidation therapy)

Reference: NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]

☒ cytarabine + daunorubicin

Cancer type: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Other criteria: FLT3 ITD negative

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Consolidation therapy)

Reference: NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]

NPM1 p.(W288Cfs*12) c.863_864insTCTG (continued)**● cytarabine + daunorubicin**

Cancer type: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Other criteria: FLT3 ITD negative

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Induction therapy); Other recommended intervention

Reference: NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]

● cytarabine + idarubicin

Cancer type: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Other criteria: FLT3 ITD negative

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Consolidation therapy)

Reference: NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]

● cytarabine + idarubicin

Cancer type: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Other criteria: FLT3 ITD negative

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Induction therapy); Other recommended intervention

Reference: NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]

● cytarabine + mitoxantrone

Cancer type: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Other criteria: FLT3 ITD negative

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Consolidation therapy)

Reference: NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]

NPM1 p.(W288Cfs*12) c.863_864insTCTG (continued)**● cytarabine + mitoxantrone**

Cancer type: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Other criteria: FLT3 ITD negative

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Induction therapy); Other recommended intervention

Reference: NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]

● gemtuzumab ozogamicin + cytarabine + daunorubicin

Cancer type: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Other criteria: CD33 positive, FLT3 ITD negative

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Consolidation therapy)
- (Induction therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]

● gemtuzumab ozogamicin + cytarabine + fludarabine + idarubicin + filgrastim

Cancer type: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Other criteria: FLT3 ITD negative

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- (Induction therapy); Other recommended intervention

Reference: NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]

Diagnostic Details

Current ESMO Information

ESMO information is current as of 2023-07-03. For the most up-to-date information, search www.esmo.org.

NPM1 p.(W288Cfs*12) c.863_864insTCTG

Diagnostic significance: Acute Myeloid Leukemia

Variant class: NPM1 mutation

Diagnostic notes:

- AML with recurrent genetic abnormalities; WHO classification of AML

Reference: ESMO Clinical Practice Guidelines - ESMO-Acute Myeloblastic Leukaemia in Adult Patients [Ann Oncol (2020); 31(6): 697-712.]

References

1. Okano et al. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. *Nat Genet.* 1998 Jul;19(3):219-20. PMID: 9662389
2. Fernandez et al. A DNA methylation fingerprint of 1628 human samples. *Genome Res.* 2012 Feb;22(2):407-19. PMID: 21613409
3. Jones et al. The epigenomics of cancer. *Cell.* 2007 Feb 23;128(4):683-92. PMID: 17320506
4. Ley et al. DNMT3A mutations in acute myeloid leukemia. *N. Engl. J. Med.* 2010 Dec 16;363(25):2424-33. PMID: 21067377
5. Marková et al. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. *Eur. J. Haematol.* 2012 Feb;88(2):128-35. PMID: 21967546
6. Yang et al. DNMT3A in haematological malignancies. *Nat. Rev. Cancer.* 2015 Mar;15(3):152-65. PMID: 25693834
7. Renneville et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. *Leukemia.* 2012 Jun;26(6):1247-54. PMID: 22289988
8. Marcucci et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. *J. Clin. Oncol.* 2012 Mar 1;30(7):742-50. PMID: 22291079
9. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
10. NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2023]
11. NCCN Guidelines® - NCCN-Myelodysplastic Syndromes [Version 1.2023]
12. Kumar et al. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations. *Hematol Oncol Stem Cell Ther.* 2018 Jun;11(2):82-89. PMID: 29079128
13. Thol et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. *J. Clin. Oncol.* 2011 Jul 20;29(21):2889-96. PMID: 21670448
14. Sandoval et al. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners. *J. Biol. Chem.* 2019 Mar 29;294(13):4898-4910. PMID: 30705090
15. Holz-Schietinger et al. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. *J. Biol. Chem.* 2012 Sep 7;287(37):30941-51. PMID: 22722925
16. Russler-Germain et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. *Cancer Cell.* 2014 Apr 14;25(4):442-54. PMID: 24656771
17. NCCN Guidelines® - NCCN-T-Cell Lymphomas [Version 1.2023]
18. Pylayeva-Gupta et al. RAS oncogenes: weaving a tumorigenic web. *Nat. Rev. Cancer.* 2011 Oct 13;11(11):761-74. PMID: 21993244
19. Karnoub et al. Ras oncogenes: split personalities. *Nat. Rev. Mol. Cell Biol.* 2008 Jul;9(7):517-31. PMID: 18568040
20. Scott et al. Therapeutic Approaches to RAS Mutation. *Cancer J.* 2016 May-Jun;22(3):165-74. doi: 10.1097/PPO.000000000000187. PMID: 27341593
21. Román et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. *Mol Cancer.* 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x. PMID: 29455666
22. Dinu et al. Prognostic significance of KRAS gene mutations in colorectal cancer—preliminary study. *J Med Life.* 2014 Oct-Dec;7(4):581-7. PMID: 25713627
23. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
24. Allegra et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. *J. Clin. Oncol.* 2016 Jan 10;34(2):179-85. PMID: 26438111
25. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf
26. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf
27. <https://assets.cwp.roche.com/f/126832/x/5738a7538b/irp230202.pdf>
28. <https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-reports-third-quarter-2022-financial-results>
29. <https://cardiffoncology.investorroom.com/2020-05-28-Cardiff-Oncology-Announces-Fast-Track-Designation-Granted-by-the-FDA-to-Onvansertib-for-Second-Line-Treatment-of-KRAS-Mutated-Colorectal-Cancer>
30. <https://bridgebio.com/news/bridgebio-pharma-announces-first-lung-cancer-patient-dosed-in-phase-1-2-trial-and-us-fda-fast-track-designation-for-shp2-inhibitor-bbp-398-in-combination-with-amgens-lumakras-sotorasib/>
31. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf
32. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf

References (continued)

33. Slebos et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. *N. Engl. J. Med.* 1990 Aug 30;323(9):561-5. PMID: 2199829
34. Box et al. Nucleophosmin: from structure and function to disease development. 2016 Aug 24;17(1):19. PMID: 27553022
35. Koike et al. Recruitment of phosphorylated NPM1 to sites of DNA damage through RNF8-dependent ubiquitin conjugates. *Cancer Res.* 2010 Sep 1;70(17):6746-56. PMID: 20713529
36. Sportoletti. How does the NPM1 mutant induce leukemia?. *Pediatr Rep.* 2011 Jun 22;3 Suppl 2:e6. PMID: 22053282
37. Hourigan et al. Accurate Medicine: Indirect Targeting of NPM1-Mutated AML. 2016 Oct;6(10):1087-1089. PMID: 27698101
38. Jain et al. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. *Leuk. Lymphoma.* 2014 Jun;55(6):1337-44. PMID: 24004182
39. Redner et al. The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties. *Blood.* 2000 Apr 15;95(8):2683-90. PMID: 10753851
40. Khoury et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia.* 2022 Jul;36(7):1703-1719. PMID: 35732831
41. Döhner et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood.* 2022 Sep 22;140(12):1345-1377. PMID: 35797463
42. NCCN Guidelines® - NCCN-Primary Cutaneous Lymphomas [Version 1.2023]